Macrogenics (MGNX) Accounts Payables (2012 - 2026)
Macrogenics (MGNX) posted quarterly Accounts Payables of $4.3 million for Q1 2026, down 35.21% year-over-year from $6.6 million in Q1 2025, and down 10.44% quarter-over-quarter from $4.8 million in Q4 2025.
Macrogenics (MGNX) Accounts Payables (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Accounts Payables for 15 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 35.21% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (down 35.21% YoY), while the FY2025 annual figure was $4.8 million, down 4.51% from the prior year.
- Accounts Payables retreated to $4.3 million in Q1 2026 per MGNX's latest filing, from $4.8 million in the prior quarter.
- Across five years, Accounts Payables topped out at $10.7 million in Q1 2024 and bottomed at $2.6 million in Q2 2022.
- Historically, Accounts Payables has averaged $5.1 million across 5 years, with a median of $4.8 million in 2025.
- Annual changes were most pronounced in 2022 — Accounts Payables tumbled 73.43% — and 2024, when it jumped 184.49%.
- Macrogenics' Accounts Payables stood at $4.9 million in 2022, then surged by 31.52% to $6.4 million in 2023, then decreased by 22.19% to $5.0 million in 2024, then retreated by 4.51% to $4.8 million in 2025, then slipped by 10.44% to $4.3 million in 2026.
- Business Quant data shows MGNX's Accounts Payables at $4.3 million in Q1 2026, $4.8 million in Q4 2025, and $5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | 4.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.29 Mn |
| Dec 31, 2025 | 4.79 Mn |
| Sep 30, 2025 | 5.94 Mn |
| Jun 30, 2025 | 4.66 Mn |
| Mar 31, 2025 | 6.62 Mn |
| Dec 31, 2024 | 5.01 Mn |
| Sep 30, 2024 | 6.61 Mn |
| Jun 30, 2024 | 5.24 Mn |
| Mar 31, 2024 | 10.69 Mn |
| Dec 31, 2023 | 6.44 Mn |
| Sep 30, 2023 | 3.30 Mn |
| Jun 30, 2023 | 3.80 Mn |
| Mar 31, 2023 | 3.76 Mn |
| Dec 31, 2022 | 4.90 Mn |
| Sep 30, 2022 | 4.62 Mn |
| Jun 30, 2022 | 2.61 Mn |
| Mar 31, 2022 | 3.73 Mn |
| Dec 31, 2021 | 15.50 Mn |
| Sep 30, 2021 | 6.17 Mn |
| Jun 30, 2021 | 9.82 Mn |